Patents by Inventor Cathy Mendelsohn

Cathy Mendelsohn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6486381
    Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptors, or the normal expression thereof, is desirable.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: November 26, 2002
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, Bristol Myers Squibb Company
    Inventors: Pierre Chambon, Thomas Lufkin, David Lohnes, Manuel Mark, Andree Dierich, Philippe Gorry, Philippe Kastner, Marianne Lemeur, Cathy Mendelsohn
  • Patent number: 6031149
    Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptors, or the normal expression thereof, is desirable.
    Type: Grant
    Filed: December 29, 1995
    Date of Patent: February 29, 2000
    Assignees: Institut National De La Sante Et De La Recherche Medicale, Centre National De La Recherche Scientifique, Universite Louis Pasteur, E.R. Squibb & Sons, Inc.
    Inventors: Pierre Chambon, Thomas Lufkin, David Lohnes, Manuel Mark, Andree Dierich, Philippe Gorry, Philippe Kastner, Marianne Lemeur, Cathy Mendelsohn
  • Patent number: 6030794
    Abstract: The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, mice which are heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous or homozygous for such deficiency. The present invention further provides the use of any of the above mice and cell lines in situations where the absence of at least one RAR or RXR receptor(s), or the normal expression thereof, is desirable.
    Type: Grant
    Filed: June 27, 1995
    Date of Patent: February 29, 2000
    Assignees: Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, E. R. Squibb & Sons, Inc.
    Inventors: Pierre Chambon, Thomas Lufkin, David Lohnes, Manuel Mark, Andree Dierich, Philippe Gorry, Philippe Kastner, Marianne Lemeur, Cathy Mendelsohn
  • Patent number: 5753521
    Abstract: The subject invention provides an isolated nucleic acid molecule which comprises nucleic acid encoding a polypeptide which has the biological activity of a receptor for picornavirus. The subject invention also provides a method which includes the-use of expression vectors in a host vector system for inducing the production of a picornavirus receptor.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: May 19, 1998
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Vincent Racaniello, Cathy Mendelsohn, Frank Costantini
  • Patent number: 5631407
    Abstract: The subject invention provides an isolated nucleic acid molecule which comprises nucleic acid encoding a polypeptide which has the biological activity of a receptor for poliovirus and in addition, provides a purified polypeptide which has this activity. The subject invention also provides a method for inducing the production of a polypeptides which includes the use of expression vectors in a host vector system. Therapeutic compositions comprising purified polypeptides which have the biological activity of a receptor for poliovirus are also provided for as are methods of treating and preventing human poliovirus infection. Further, the subject invention provides a method of producing a transgenic animal expressing human poliovirus receptors.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: May 20, 1997
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Vincent Racaniello, Cathy Mendelsohn, Frank Costantini